Reimagine the health of your patients by targeting the gut microbiome

Using cutting-edge technology and microbiome science, Pendulum has identified proprietary strains, like Akkermansia muciniphila, that increase synthesis of health-promoting postbiotics and strengthen gut barrier integrity.

In a clinical trial, Pendulum’s flagship product Pendulum Glucose Control, a blend of Akkermansia muciniphila and four other high-potency bacterial strains, was shown to help lower A1C and post-meal glucose spikes in people with type 2 diabetes taking metformin.

Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s clinically-studied strains, is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.

Want to become a Pendulum partner?

We’d love to share how our partnership program works.

Pendulum Glucose Control is more than a probiotic, it’s a medical food

Medical foods are a special product category distinct from pharmaceuticals, conventional foods, and supplements. 

As defined by Congress in the Orphan Drug Act, the term medical food, is: A food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements based on recognized scientific principles, are established by medical evaluation.

In other words, Pendulum Glucose Control is uniquely designed to help with the dietary management of Type 2 diabetes.

Have a question or want more info about Pendulum products?

Drop us a line at hcpinfo@pendulumlife.com.

Resources for you and your practice

From Ph.D.s to MDs to RDs, we’re surrounded by smarts.

We’ve partnered with top doctors, researchers, and scientists from pretty impressive institutions—like Stanford, Johns Hopkins, UCLA, Mayo Clinic, and the American Diabetes Association.

Our medical research team is led by Chief Medical Officer Orville Kolterman, MD. Dr. Kolterman is a diabetes expert and previous Chief Medical Officer at Amylin Pharmaceuticals, where he brought four diabetes drugs from early-stage development through trials to market.

Together with Dr. Kolterman, we work with leading diabetes professionals to ensure our products deliver results and meet the highest standards of efficacy and safety.

John Buse, MD John Buse, MD

John Buse, MD

Chair, Division of Endocrinology
University of North Carolina School of Medicine

Purna Kashyap, MBBS Purna Kashyap, MBBS

Purna Kashyap, MBBS

Associate Professor, Medicine
Mayo Clinic

Davida Krueger, NP Davida Krueger, NP

Davida Krueger, NP

Nurse Practitioner
Henry Ford Health System

Chair
American Diabetes Association (ADA) Research Foundation

Emeran Mayer, MD Emeran Mayer, MD

Emeran Mayer, MD

Director, Oppenheimer Center For Neurobiology of Stress and Resilience

Professor, Department of Medicine
UCLA

Jay Pasricha, MD Jay Pasricha, MD

Jay Pasricha, MD

Director, Neurogastroenterology Vice Chair, Medicine Innovation and Commercialization
Johns Hopkins University

Anne Peters, MD Anne Peters, MD

Anne Peters, MD

Director, Clinical Diabetes
University of Southern California Private Practice

Robert Ratner, MD Robert Ratner, MD

Robert Ratner, MD

Chief Medical Officer
Virta Health

Fmr Chief Scientific & Medical Officer
American Diabetes Association

Carol Wysham, MD Carol Wysham, MD

Carol Wysham, MD

Professor
University of Washington

Practitioner
Rockwood Multicare Center for Diabetes

Chris Mason, Ph.D. Chris Mason, Ph.D.

Chris Mason, Ph.D.

Associate Professor, Integrative Functional Genomics, Clinical Genetics and Synthetic Biology
Cornell University

Eric Schadt, Ph.D. Eric Schadt, Ph.D.

Eric Schadt, Ph.D.

CEO
Sema4

Dean Precision Medicine
Mount Sinai Medicine

Alfred Spormann, Ph.D. Alfred Spormann, Ph.D.

Alfred Spormann, Ph.D.

Professor, Civil and Environmental Engineering
Stanford University

Peter Turnbaugh, Ph.D Peter Turnbaugh, Ph.D

Peter Turnbaugh, Ph.D

Assistant Professor, Department of Microbiology and Immunology
UCSF

Dietrich Stephan, Ph.D. Dietrich Stephan, Ph.D.

Dietrich Stephan, Ph.D.

CEO
Neubase Therapeutics

Chair, Department of Human Genetics
University of Pittsburgh